Susquehanna International Group’s Checkpoint Therapeutics CKPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-195,200
| Closed | -$789K | – | 12749 |
|
|
2025
Q1 | $789K | Buy |
195,200
+111,600
| +133% | +$372K | ﹤0.01% | 7860 |
|
|
2024
Q4 | $268K | Buy |
83,600
+45,000
| +117% | +$153K | ﹤0.01% | 10080 |
|
|
2024
Q3 | $86.5K | Buy |
38,600
+17,000
| +79% | +$39.2K | ﹤0.01% | 11136 |
|
|
2024
Q2 | $46.4K | Sell |
21,600
-71,600
| -77% | -$127K | ﹤0.01% | 11443 |
|
|
2024
Q1 | $191K | Buy |
93,200
+35,900
| +63% | +$71.6K | ﹤0.01% | 10637 |
|
|
2023
Q4 | $131K | Buy |
57,300
+36,800
| +180% | +$80.1K | ﹤0.01% | 11095 |
|
|
2023
Q3 | $34.9K | Sell |
20,500
-11,200
| -35% | -$25.5K | ﹤0.01% | 11429 |
|
|
2023
Q2 | $78.3K | Buy |
31,700
+6,700
| +27% | +$18.3K | ﹤0.01% | 11116 |
|
|
2023
Q1 | $56.3K | Buy |
+25,000
| New | +$125K | ﹤0.01% | 11645 |
|
|
2022
Q2 | – | Sell |
-1,170
| Closed | -$21K | – | 12985 |
|
|
2022
Q1 | $21K | Sell |
1,170
-980
| -46% | -$21K | ﹤0.01% | 12609 |
|
|
2021
Q4 | $67K | Sell |
2,150
-1,270
| -37% | -$42.1K | ﹤0.01% | 12402 |
|
|
2021
Q3 | $113K | Sell |
3,420
-5,270
| -61% | -$156K | ﹤0.01% | 11985 |
|
|
2021
Q2 | $256K | Buy |
+8,690
| New | +$241K | ﹤0.01% | 11098 |
|
Susquehanna International Group's CKPT Position: Q2 2025 in Review
Susquehanna International Group sold out of Checkpoint Therapeutics (CKPT) in Q2 2025, closing a stake of 251,213 shares — an estimated $1.01M sold.
Susquehanna International Group first reported a position in CKPT in Q2 2018 and held it in 22 quarters. The position peaked at $2.63M in Q4 2021. 0 funds tracked by Wall St. Rank hold CKPT as of Q2 2025.
- Susquehanna International Group reported no remaining Checkpoint Therapeutics position as of Q2 2025 after selling out during the quarter.
- Susquehanna International Group sold 251,213 Checkpoint Therapeutics shares in Q2 2025, an estimated $1.01M.
- Susquehanna International Group first reported a position in Checkpoint Therapeutics in Q2 2018 and held it in 22 quarters.
- Susquehanna International Group's Checkpoint Therapeutics position peaked at $2.63M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q2 2025.
Based on Susquehanna International Group's 13F filing for Q2 2025, filed 14 Aug 2025.